Chronic Rhinosinusitis (CRS)NCT06834477
Impact of Structural and Microenvironmental Abnormalities in Olfactory Cleft on Olfaction in CRS
An observational study of Chronic Rhinosinusitis (CRS), run by Peking University Third Hospital at 1 site in China.
Trial summary
The purpose of this research is to investigate the impact of structural abnormalities and microenvironmental changes in the olfactory cleft on olfactory function in patients with chronic rhinosinusitis (CRS). Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Chronic Rhinosinusitis (CRS)
- What is being tested?
- Computed Tomography
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- 14 Mar 2025to 14 Mar 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Surgical patients were recruited from the Department of Otolaryngology at Peking University Third Hospital in clinic.
Who may be able to join
- Diagnosed with CRS based on the diagnostic criteria of the EPOS guideline.
- Provision of signed and dated informed consent form.
- Patients with CRS admitted to the hospital awaiting endoscopic sinus surgery.
- Healthy controls undergoing surgery for the deviated septum.
- Provision of signed and dated informed consent form.
Who cannot join
- Those who have taken oral glucocorticoids, antibiotics, anti-leukotrienes, and antihistamines within four weeks.
- Patients who have had prior sinus surgery.
- Patients with fungal sinusitis, inverted papilloma, or other nasal diseases.
- Patients with a diagnosis of immune suppression or suspicion of malignancy that may be affecting the nose/paranasal sinuses.
- Patients who are mentally or physically unable to perform olfactory tests
- Patients with nasal polyps, sinusitis, nasal cavity tumors and other diseases.
Show all 9Show fewer
- Patients with hyposmia or anosmia.
- Patients with diagnosed neurodegenerative disease.
- Patients who are mentally or physically unable to perform olfactory tests.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Department of Otolaryngology Head and Neck Surgery, Peking University Third Hospital, Beijing, People's Republic of China
Beijing, Haidian District, 10019
Dawei Wu, MD, PhD, +86-10-13522503401, davidwuorl@163.com
About this study
Official title: The Influence of Structural and Microenvironmental Abnormalities in the Olfactory Cleft on Olfactory Function in Patients With Chronic Rhinosinusitis
The purpose of this research is to investigate the impact of structural abnormalities and microenvironmental changes in the olfactory cleft on olfactory function in patients with chronic rhinosinusitis (CRS). It sought to elucidate the complex relationships among structural abnormalities, microenvironmental changes, and inflammatory factors contributing to olfactory dysfunction through a multidimensional assessment encompassing imaging, aerodynamics, biomarker , and histopathology analysis.
Read the detailed description
Olfactory dysfunction (OD) is a critical symptom among patients with CRS, affecting up to 83% of individuals with the condition. Currently, it is considered that the inflammation in olfactory cleft is a central factor contributing to both conductive and sensorineural OD in patients with CRS. Inflammation in the olfactory cleft could impair olfaction by altering the mucosal and mucus microenvironment thereby causing damage to the olfactory neuroepithelium, by physically impeding delivery of odorant-containing air to the olfactory cleft, or a combination of both mechanisms.
Existing studies mainly focus on isolated mechanisms, such as inflammation-induced physical obstruction or injury of olfactory epithelium. However, limited research has explored how structural abnormalities and microenvironmental changes in the olfactory cleft might interact to contribute to olfactory dysfunction. This research aimed to evaluate the relationship between structural abnormalities and microenvironmental changes in the olfactory cleft and their impact on olfactory function in patients with CRS using a multidimensional approach integrating imaging, pathology, and functional analysis.
This is a retrospective study. Patients with CRS admitted for endoscopic sinus surgery (n = 70) and healthy controls undergoing surgery for the deviated septum (n = 10) were included. All the participants had undergone:
- Clinical assessment of olfactory function and quality of life
- Olfactory measurements had been conducted preoperatively using the Sniffin' Sticks Test to evaluate olfactory threshold (OT), olfactory discrimination (OD), olfactory identification (OI), and the overall composite scores (TDI). A TDI score > 30.75, 16-30.75, and ≤ 15 indicates normosmia, hyposmia, and anosmia, respectively.
- The 22-item Sino-Nasal Outcome Test (SNOT-22) had been administered to evaluate patient-reported subjective outcomes.
- The Questionnaire of Olfactory Disorders Negative Statements (QOD-NS) was utilized to assess the olfactory-specific quality of life.
- The visual analog scale(VAS)for olfaction was employed to measure patients' self-reported olfaction.
- Evaluation of structural abnormalities and patency of the olfactory cleft Computed tomography scans were obtained in every participant. The anterior boundary of OC is defined by the anterior attachment of the middle turbinate; the posterior boundary corresponding to the anterior face of the sphenoid sinus; the lateral boundaries are defined as the attachment of the middle and/or superior turbinate laterally and the nasal septum medially. The olfactory cleft is further divided into anterior and posterior, divided by the anterior end of the superior turbinate. The olfactory cleft opacification is defined as the normal airway filled with a value representing soft tissue and /or presence of close contact between the nasal turbinates and the nasal septum. The opacification percentage in the anterior olfactory cleft is calculated using the lower margin of the middle turbinate and the cribriform plate as the vertical boundaries. The opacification percentage in the posterior olfactory cleft is calculated using the lower margin of the superior turbinate and the cribriform plate as the vertical boundaries. The olfactory cleft opacifications were graded on a scale of 0-4 by the ratio of the opacified area to the whole area of the corresponding region of the olfactory cleft, with 0 (no opacification), 1 (25%), 2 (25%-50%), 3 (50%-75%), and 4 (>75%). Then we evaluated:
- The original version of olfactory cleft CT score, calculated as the sum of the anterior and posterior olfactory cleft opacification scores, ranged from 1 to 8.
- The modified version of olfactory cleft CT score: CT scores for unilateral olfactory cleft, including the anterior and posterior regions, specifically the left anterior, left posterior, right anterior, and right posterior olfactory cleft, as well as their total sum. Additionally, a more detailed assessment is performed by recording whether opacification is present at the apex and the middle-lower portion of each olfactory cleft subregion. Each subregion is further divided into anterior, middle, and posterior areas, with each area being independently assessed. A score of 1 is assigned if opacification is observed, and 0 if absent. To further quantify the impact of olfactory cleft obstruction on olfactory airflow, this study employs three-dimensional modeling and computational fluid dynamics (CFD) analysis of the nasal cavity based on CT imaging data of sinuses. The air flow, velocity, pressure, and air flow ratio in the olfactory cleft were obtained by the hydrodynamics analysis method.
- Evaluation of the mucus and mucosal microenvironment in the olfactory cleft
- Patients with CRS were categorized into two clinical phenotypes, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP), based on histology and physical examination.
- To investigate the inflammatory phenotypes of CRS, hematoxylin and eosin (H\&E) staining were performed to identify the predominant inflammatory cell types within the lamina propria. Patients with CRS were divided into eosinophilic CRS and non-eosinophilic CRS. The eosinophilic phenotype of CRS was defined when the frequency of tissue eosinophils exceeded 10% of the total infiltrating cells per high-power field.
- Olfactory cleft mucus was collected to quantify the level of olfactory cleft mucus galectin-10 and eosinophil-derived neurotoxin (EDN) using commercial human enzyme-linked immunosorbent assay kits. Th1/Th2-related cytokines, including IL-2, IL-4, IL-5, IL-6, IFN-γ, TNF, and IL-10, were detected using a flow cytometry-based bead array (CBA) capture assay.
- Olfactory cleft mucosal specimens were collected from the anterior portion of the superior turbinate using a through-cut forceps during surgery for immunohistochemical analysis of olfactory marker protein (OMP), to evaluate the expression levels of mature olfactory neurons.
- Conditions
- Chronic Rhinosinusitis (CRS)
- Being tested
- Computed Tomography
- Keywords
- olfactory cleft, olfactory dysfunction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Computed TomographyOther
Also called collection of superior turbinate biopsy specimens, collection of olfactory cleft mucus
low-dose CT is taken
| Study group | Role | What they receive |
|---|---|---|
| Patients with CRS admitted for endoscopic sinus surgery | Not described Receives: Other: Computed Tomography | |
| healthy controls undergoing surgery for the deviated septum | Not described Receives: Other: Computed Tomography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sniffin Sticks Test
The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test.
The final TDI score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores.
Measured: Immediately before surgery
Secondary outcomes (12)
The 22-item Sino-Nasal Outcome Test (SNOT-22)
Measured: Immediately before surgery
Visual analog scale(VAS)for olfaction
numerical rating scale from 0 (no smell) to 10 (perfect smell)
Measured: Immediately before surgery
The Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)
The QOD-NS comprises 17 negatively phrased statements, each rated on a scale from 0 (disagree) to 3 (agree), yielding a maximum score of 51. Higher QOD-NS scores indicate a poorer quality of life.
Measured: Immediately before surgery
The original version of olfactory cleft CT score
Measured: during routine preoperative CT imaging
The modified version of olfactory cleft CT score
Measured: during routine preoperative CT imaging
Airflow velocity in the olfactory cleft
one of the airflow parameters in the olfactory cleft that can be obtained by CFD analysis
Measured: Immediately after CT scans
Mass flowrate in the olfactory cleft
One of the airflow parameters in the olfactory cleft that can be obtained by CFD analysis
Measured: Immediately after CT scans
Airflow ratio in the olfactory cleft
one of the airflow parameters in the olfactory cleft that can be obtained by CFD analysis. The airflow ratio was calculated as the mass flowrate through the OC relative to the total airflow rate through the nasal cavity.
Measured: Immediately after CT scans
The level of eosinophil-derived neurotoxin, galectin-10 and otherTh1/Th2-related cytokines in olfactory cleft mucus
The levels of galectin-10 and eosinophil-derived neurotoxin (EDN) in olfactory cleft mucus were measured by commercial human enzyme-linked immunosorbent assay kits. Th1/Th2-related cytokines, including IL-2, IL-4, IL-5, IL-6, IFN-γ, TNF, and IL-10, were detected using a flow cytometry-based bead array (CBA) capture assay.
Measured: Immediately after surgery
Clinical phenotypes classification:CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP)
Measured: During preoperative physical and imaging examinations
Histopathological phenotypes classification: eosinophilic CRS or non-eosinophilic CRS
Hematoxylin and eosin (H\&E) staining are performed to identify the predominant inflammatory cell types within the lamina propria. Patients with CRS were divided into eosinophilic CRS and non-eosinophilic CRS.
Measured: Immediately after surgery
Immunohistochemical staining of olfactory marker protein (OMP) in olfactory epithelium
The OMP is a kind of biomarker for mature olfactory sensory neurons. This parameter may indicate the inflammation-induced neurological damage in olfactory epithelium.
Measured: Immediately after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2025
- Study start14 Mar 2025 (estimated)
- Primary completion14 Mar 2027 (estimated)
- Study completion14 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Rhinosinusitis (CRS)Studies of the same condition, open and under way.
- More trials run by Peking University Third HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Peking University Third Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dawei Wu, Peking University Third Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06834477
- Sponsor's protocol ID
- 9059102
- Status last verified
- Feb 2025
- First submitted
- 6 Feb 2025
- Last updated
- 19 Feb 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We will decide whether to share the individual participant data after the study.
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Influence of Structural and Microenvironmental Abnormalities in the Olfactory Cleft on Olfactory Function in Patients With Chronic Rhinosinusitis
- ClinicalTrials.gov ID
- NCT06834477
- Acronym / sponsor ID
- 9059102
- Conditions
- Chronic Rhinosinusitis (CRS)
- Keywords
- olfactory cleft, olfactory dysfunction
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Peking University Third HospitalUniversity, hospital or other
- Study start
- 14 Mar 2025 (estimated)
- Primary completion
- 14 Mar 2027 (estimated)
- Study completion
- 14 Mar 2027 (estimated)
- First posted
- 19 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research is to investigate the impact of structural abnormalities and microenvironmental changes in the olfactory cleft on olfactory function in patients with chronic rhinosinusitis (CRS). It sought to elucidate the complex relationships among structural abnormalities, microenvironmental changes, and inflammatory factors contributing to olfactory dysfunction through a multidimensional assessment encompassing imaging, aerodynamics, biomarker , and histopathology analysis.
Detailed description
Olfactory dysfunction (OD) is a critical symptom among patients with CRS, affecting up to 83% of individuals with the condition. Currently, it is considered that the inflammation in olfactory cleft is a central factor contributing to both conductive and sensorineural OD in patients with CRS. Inflammation in the olfactory cleft could impair olfaction by altering the mucosal and mucus microenvironment thereby causing damage to the olfactory neuroepithelium, by physically impeding delivery of odorant-containing air to the olfactory cleft, or a combination of both mechanisms.
Existing studies mainly focus on isolated mechanisms, such as inflammation-induced physical obstruction or injury of olfactory epithelium. However, limited research has explored how structural abnormalities and microenvironmental changes in the olfactory cleft might interact to contribute to olfactory dysfunction. This research aimed to evaluate the relationship between structural abnormalities and microenvironmental changes in the olfactory cleft and their impact on olfactory function in patients with CRS using a multidimensional approach integrating imaging, pathology, and functional analysis.
This is a retrospective study. Patients with CRS admitted for endoscopic sinus surgery (n = 70) and healthy controls undergoing surgery for the deviated septum (n = 10) were included. All the participants had undergone:
- Clinical assessment of olfactory function and quality of life
- Olfactory measurements had been conducted preoperatively using the Sniffin' Sticks Test to evaluate olfactory threshold (OT), olfactory discrimination (OD), olfactory identification (OI), and the overall composite scores (TDI). A TDI score > 30.75, 16-30.75, and ≤ 15 indicates normosmia, hyposmia, and anosmia, respectively.
- The 22-item Sino-Nasal Outcome Test (SNOT-22) had been administered to evaluate patient-reported subjective outcomes.
- The Questionnaire of Olfactory Disorders Negative Statements (QOD-NS) was utilized to assess the olfactory-specific quality of life.
- The visual analog scale(VAS)for olfaction was employed to measure patients' self-reported olfaction.
- Evaluation of structural abnormalities and patency of the olfactory cleft Computed tomography scans were obtained in every participant. The anterior boundary of OC is defined by the anterior attachment of the middle turbinate; the posterior boundary corresponding to the anterior face of the sphenoid sinus; the lateral boundaries are defined as the attachment of the middle and/or superior turbinate laterally and the nasal septum medially. The olfactory cleft is further divided into anterior and posterior, divided by the anterior end of the superior turbinate. The olfactory cleft opacification is defined as the normal airway filled with a value representing soft tissue and /or presence of close contact between the nasal turbinates and the nasal septum. The opacification percentage in the anterior olfactory cleft is calculated using the lower margin of the middle turbinate and the cribriform plate as the vertical boundaries. The opacification percentage in the posterior olfactory cleft is calculated using the lower margin of the superior turbinate and the cribriform plate as the vertical boundaries. The olfactory cleft opacifications were graded on a scale of 0-4 by the ratio of the opacified area to the whole area of the corresponding region of the olfactory cleft, with 0 (no opacification), 1 (25%), 2 (25%-50%), 3 (50%-75%), and 4 (>75%). Then we evaluated:
- The original version of olfactory cleft CT score, calculated as the sum of the anterior and posterior olfactory cleft opacification scores, ranged from 1 to 8.
- The modified version of olfactory cleft CT score: CT scores for unilateral olfactory cleft, including the anterior and posterior regions, specifically the left anterior, left posterior, right anterior, and right posterior olfactory cleft, as well as their total sum. Additionally, a more detailed assessment is performed by recording whether opacification is present at the apex and the middle-lower portion of each olfactory cleft subregion. Each subregion is further divided into anterior, middle, and posterior areas, with each area being independently assessed. A score of 1 is assigned if opacification is observed, and 0 if absent. To further quantify the impact of olfactory cleft obstruction on olfactory airflow, this study employs three-dimensional modeling and computational fluid dynamics (CFD) analysis of the nasal cavity based on CT imaging data of sinuses. The air flow, velocity, pressure, and air flow ratio in the olfactory cleft were obtained by the hydrodynamics analysis method.
- Evaluation of the mucus and mucosal microenvironment in the olfactory cleft
- Patients with CRS were categorized into two clinical phenotypes, CRS with nasal polyps (CRSwNP) and CRS without nasal polyps (CRSsNP), based on histology and physical examination.
- To investigate the inflammatory phenotypes of CRS, hematoxylin and eosin (H\&E) staining were performed to identify the predominant inflammatory cell types within the lamina propria. Patients with CRS were divided into eosinophilic CRS and non-eosinophilic CRS. The eosinophilic phenotype of CRS was defined when the frequency of tissue eosinophils exceeded 10% of the total infiltrating cells per high-power field.
- Olfactory cleft mucus was collected to quantify the level of olfactory cleft mucus galectin-10 and eosinophil-derived neurotoxin (EDN) using commercial human enzyme-linked immunosorbent assay kits. Th1/Th2-related cytokines, including IL-2, IL-4, IL-5, IL-6, IFN-γ, TNF, and IL-10, were detected using a flow cytometry-based bead array (CBA) capture assay.
- Olfactory cleft mucosal specimens were collected from the anterior portion of the superior turbinate using a through-cut forceps during surgery for immunohistochemical analysis of olfactory marker protein (OMP), to evaluate the expression levels of mature olfactory neurons.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with CRS admitted for endoscopic sinus surgery | – | Other: Computed Tomography |
| healthy controls undergoing surgery for the deviated septum | – | Other: Computed Tomography |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Surgical patients were recruited from the Department of Otolaryngology at Peking University Third Hospital in clinic.
Key inclusion criteria (5 listed)
- Diagnosed with CRS based on the diagnostic criteria of the EPOS guideline.
- Provision of signed and dated informed consent form.
- Patients with CRS admitted to the hospital awaiting endoscopic sinus surgery.
- Healthy controls undergoing surgery for the deviated septum.
- Provision of signed and dated informed consent form.
Key exclusion criteria (9 listed)
- Those who have taken oral glucocorticoids, antibiotics, anti-leukotrienes, and antihistamines within four weeks.
- Patients who have had prior sinus surgery.
- Patients with fungal sinusitis, inverted papilloma, or other nasal diseases.
- Patients with a diagnosis of immune suppression or suspicion of malignancy that may be affecting the nose/paranasal sinuses.
- Patients who are mentally or physically unable to perform olfactory tests
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Computed TomographyAlso: collection of superior turbinate biopsy specimens, collection of olfactory cleft mucuslow-dose CT is taken | Other | Patients with CRS admitted for endoscopic sinus surgery, healthy controls undergoing surgery for the deviated septum |
Primary outcome
Sniffin Sticks Test
Time frame: Immediately before surgery
The test consists of odorous rods that are presented to the patient's nose. It consists of 3 parts different, with 3 sets of corresponding sticks: an olfactory threshold test, an olfactory discrimination test and an olfactory identification test. The final TDI score, out of 48, is the sum of the olfactory threshold, discrimination and identification scores.
12 secondary outcomes
The 22-item Sino-Nasal Outcome Test (SNOT-22)
Time frame: Immediately before surgery
Visual analog scale(VAS)for olfaction
Time frame: Immediately before surgery
The Questionnaire of Olfactory Disorders Negative Statements (QOD-NS)
Time frame: Immediately before surgery
The original version of olfactory cleft CT score
Time frame: during routine preoperative CT imaging
The modified version of olfactory cleft CT score
Time frame: during routine preoperative CT imaging
Airflow velocity in the olfactory cleft
Time frame: Immediately after CT scans
Mass flowrate in the olfactory cleft
Time frame: Immediately after CT scans
Airflow ratio in the olfactory cleft
Time frame: Immediately after CT scans
The level of eosinophil-derived neurotoxin, galectin-10 and otherTh1/Th2-related cytokines in olfactory cleft mucus
Time frame: Immediately after surgery
Clinical phenotypes classification:CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP)
Time frame: During preoperative physical and imaging examinations
Histopathological phenotypes classification: eosinophilic CRS or non-eosinophilic CRS
Time frame: Immediately after surgery
Immunohistochemical staining of olfactory marker protein (OMP) in olfactory epithelium
Time frame: Immediately after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2025.
- Individual participant dataSharing planned: No. We will decide whether to share the individual participant data after the study.
Related trials for Chronic Rhinosinusitis (CRS)
Recruiting
Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Active, not recruitingObservational study
Endotypic Stability in CRS
Chronic Sinusitis
Not yet recruiting
Position-Directed Budesonide Nasal Drops for CRS-associated Olfactory Dysfunction
Chronic Rhinosinusitis (CRS), Olfactory Dysfunction
RecruitingPhase 4
Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS).
Chronic Rhinosinusitis With Nasal Polyps
RecruitingObservational study
CRS Questionnaire Validation Project
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Rhinosinusitis (CRS), run by Peking University Third Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Feb 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dawei Wu, MD, PhD (+86-10-13522503401, davidwuorl@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sniffin Sticks Test (time frame: Immediately before surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2025.